- Home
- CELC vs EOSE Comparison
CELC vs EOSE Comparison
Compare CELC & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- EOSE
- Stock Information
- Founded
- CELC 2011
- EOSE 2008
- Country
- CELC United States
- EOSE United States
- Employees
- CELC N/A
- EOSE N/A
- Industry
- CELC Medical Specialities
- EOSE Industrial Machinery/Components
- Sector
- CELC Health Care
- EOSE Miscellaneous
- Exchange
- CELC Nasdaq
- EOSE Nasdaq
- Market Cap
- CELC 594.7M
- EOSE 542.2M
- IPO Year
- CELC 2017
- EOSE N/A
- Fundamental
- Price
- CELC $12.66
- EOSE $2.19
- Analyst Decision
- CELC Strong Buy
- EOSE Strong Buy
- Analyst Count
- CELC 6
- EOSE 6
- Target Price
- CELC $29.17
- EOSE $5.42
- AVG Volume (30 Days)
- CELC 257.7K
- EOSE 7.5M
- Earning Date
- CELC 11-14-2024
- EOSE 11-05-2024
- Dividend Yield
- CELC N/A
- EOSE N/A
- EPS Growth
- CELC N/A
- EOSE N/A
- EPS
- CELC N/A
- EOSE N/A
- Revenue
- CELC N/A
- EOSE $14,963,000.00
- Revenue This Year
- CELC N/A
- EOSE $187.90
- Revenue Next Year
- CELC N/A
- EOSE $391.53
- P/E Ratio
- CELC N/A
- EOSE N/A
- Revenue Growth
- CELC N/A
- EOSE 20.34
- 52 Week Low
- CELC $11.51
- EOSE $0.61
- 52 Week High
- CELC $22.19
- EOSE $3.66
- Technical
- Relative Strength Index (RSI)
- CELC 28.22
- EOSE 33.48
- Support Level
- CELC $15.33
- EOSE $2.23
- Resistance Level
- CELC $16.14
- EOSE $2.52
- Average True Range (ATR)
- CELC 0.97
- EOSE 0.26
- MACD
- CELC -0.28
- EOSE -0.12
- Stochastic Oscillator
- CELC 22.85
- EOSE 2.11
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.